In a phase 1 trial by Martin and colleagues, observations at week 6 comparing tirzepatide vs once-daily liraglutide and placebo have shown that the use of the latter, provides a reduction on the desire for high-fat and high-sugar food by lowering activation in the cingulate gyri, hippocampus and orbitofrontal cortex assessed by MRI and blood-oxygen-level at these areas, meaning less appetite, early satiety, and less food craving with more reduction on weight loss at short term (181)
The simplest answer is: The results should not be treated as a direct head-to-head comparison because they come from separate clinical trials
It works on both GLP-1 and another hormone receptor, GIP
Patients in Utah often ask what influences the maximum dose of ozempic for weight loss
When appetite is suppressed, and portions shrink, protein often gets displaced by easier-to-eat options that require less chewing and feel lighter in the stomach